SHIJIAZHUANG, China, April 27, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) has obtained approval from the Ministry of Public Health of Ecuador for the sale and promotion of the Lianhua Qingwen Capsule (Granule) ("Lianhua Qingwen") in the country. The approval officially registers Lianhua Qingwen—a traditional Chinese medicine (TCM) mainly used for treating colds and influenza—under the "natural medicine" category.
"We are delighted that Lianhua Qingwen continues to be recognized by global communities. This approval marks the culmination of years of development and research, and is the latest milestone in our mission to bring the benefits of TCM to patients worldwide," said Xiangjun Wu, GM of Yiling Pharmaceutical.
"Moving forward, we hope our TCM solutions will be embraced by more medical practitioners. This will enable us to continue finding innovative solutions to harness our medicines in the global fight against pandemics and epidemics."
Comprised of 11 herbs, gypsum and menthol, Lianhua Qingwen has shown curative effects against mild symptoms caused by the common cold and influenza, and was the first new medicine approved by the National Medical Products Administration of China during the SARS epidemic in 2003. To date, nations including Brazil, Indonesia, Canada, Mozambique and Romania have granted marketing authorization to Lianhua Qingwen and registered it as an herbal medicine or natural health product.
Lianhua Qingwen was also included in China's National Essential Medicines List and National Medical Care List (A category), and has been added as a recommended medicine for the alleviation of mild symptoms of COVID-19 in the "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia" (Trial Version 4/5/6/7), issued by the General Office of the National Health and Health Commission of China and Office of the State Administration of Traditional Chinese Medicine.
In addition, the State Drug Administration of China recently approved the supplemental drug application for new indications of Lianhua Qingwen, adding "functional indications" to the previously approved indication: "For mild/common types of fever, cough and fatigue in the conventional treatment of novel coronavirus pneumonia."
Multiple studies have reported Lianhua Qingwen demonstrates antiviral effects in patients with COVID-19. The latest clinical trial led by Chinese respiratory experts evaluates the efficacy of the medicine in the treatment of coronavirus pneumonia, and found that patients administered with the medicine displayed improved lung recovery compared to the control group.
